November 24, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Share:
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy
 

Tokyo, May 12, 2014 (JCN) - Takara Bio Inc. has submitted an Investigational New Drug (IND) application to the Food and Drug Administration (FDA) dated April 30, 2014 in order to conduct a phase II clinical trial in the United States of the oncolytic virus HF10 in patients with unresected or metastatic malignant melanoma.

In this trial, the efficacy, safety and tolerability of HF10 treatment in combination with Ipilimumab (YERVOY), anti-CTLA-4 monoclonal antibody, will be evaluated in patients with Stage IIIB, IIIC or IV unresected or metastatic malignant melanoma.

The principal investigator of the study will be Dr.Robert Andtbacka, an associate professor of surgical oncology in the Department of Surgery, University of Utah Huntsman Cancer Institute. Approximately nine clinical sites in the USA will participate in the study.

It is planned that at least 43 patients will be enrolled during the 2 year study period. The enrollment will start following FDA review and the approval from the review committees of the clinical sites.

As of April 4, Takara Bio had completed enrollment of a Phase I clinical trial of HF10 in patients with solid tumors in the US. This trial was conducted to evaluate single and repeated intratumoral injections of the oncolytic virus, HF10.

Based on the results of the Phase I, treatment with intratumorally-injected HF10 was found to be well tolerated in multiple types of solid tumor malignancies.

Takara Bio aims to commercialize the HF10 anti-cancer therapy by the fiscal year ending in March 2019.

By Jun Ota Staff Writer

Copyright © 2014 JCN. All rights reserved. A division of Japan Corporate News Network KK.


 Company Profile |   Print  |   Alerts
ACN Newswire

 Recent  Takara Bio  News  
  Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy  (May 12, 2014)
  Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy  (Apr 10, 2014)
  Takara Bio to Distribute ZENOAQ's Cell Cryopreservation Medium in Japan, Europe, and North America  (July 26, 2013)
  Takara Bio launches Nippi's iMatrix-511 Worldwide  (July 12, 2013)
  Takara Bio Grants Cellular Dynamics a Commercial License to Use RetroNectin for iPSC Production  (June 24, 2013)
  Takara Bio Licenses Mushroom Production Technology to Sun Toward Tech  (June 13, 2013)
  Takara Bio Initiates Phase 1 HIV Gene Therapy Clinical Trial  (Jan 7, 2013)
  Takara Bio Submits IND Application for HIV-1 Gene Therapy to the FDA  (Mar 23, 2012)
  Takara Bio and Tianjin Medical University in Gene Therapy Project  (Aug 3, 2011)
  Takara Bio RetroNectin to UCLA for TCR-gene Therapy Clinical Trials in Advanced Melanoma  (Dec 18, 2008)



 Recent  Biotech News   
Otsuka Group Establishes New Company; Strengthens Presence in Vending Machine Market (Nov 17, 2014)
Otsuka's 'QuickNavi-Flu' Diagnostic Kit to Provide Additional Diagnosis-Related Information (Oct 14, 2014)
Nitto Denko Anti-fibrosis Drug Starts Phase-1b Dosing for Cirrhosis Patients in the US (Oct 10, 2014)
Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Yokogawa Technology Selected for JSTA's Next-generation Technology Transfer Program (Aug 8, 2014)
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation (Apr 24, 2014)
Kaneka, RIKEN Synthesize Bioplastic from Non-food Plant Resources
 (Apr 14, 2014)
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)

More Biotech news...
 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)